Bremelanotide stability: 8 degradants

A paper published in Analytical Methods on 22 July 2026 mapped, for the first time, all eight degradation products that form when bremelanotide (PT-141) is stressed under the conditions pharmaceutical manufacturers use to test shelf life. The study by V K Yuvaraaj and Nitish Sharma combined liquid chromatography with high-resolution tandem mass spectrometry (LC-HRMS/MS) and computational energy-minimization modelling to characterize each degradant and predict which carbon centers in the cyclic peptide are most prone to losing their stereochemical configuration^[1].

Why degradant characterization matters for a cyclic peptide therapeutic

Bremelanotide is a cyclic heptapeptide: a seven-amino-acid chain closed into a lactam bridge that makes it more resistant to enzymatic cleavage than a linear peptide, but also means that when it does break down, the products can be structurally complex. The FDA-approved product, Vyleesi (1.75 mg subcutaneous autoinjector), must meet International Council for Harmonisation (ICH) quality standards, which require a sponsor to identify, characterize, and assess the toxicological significance of any degradant present above a defined threshold^[4]. For grey-market research vials sold as "PT-141," no such obligation applies, which is why analytical work like this is directly relevant to anyone trying to understand what is in an unlicensed product.

What the forced-degradation study found

Yuvaraaj and Sharma subjected bremelanotide acetate to six ICH-mandated stress conditions: acidic, basic, neutral hydrolysis, oxidative, thermal, and photolytic. Eight degradation products emerged and were characterized by their MS/MS fragmentation patterns. The compound showed lower degradation under acidic conditions than under basic conditions and was significantly susceptible to oxidative stress^[1]. The dominant degradation pathways identified were deacetylation (loss of the acetate counterion), peptide-bond hydrolysis, oxidation of susceptible residues, and epimerization, the inversion of a chiral carbon center that converts one stereoisomer into a different one.

Epimerization is particularly worth examining in cyclic peptides. Because the ring constrains backbone geometry, even a single center flipping its configuration can change the three-dimensional shape enough to alter receptor binding. The paper used energy minimization calculations to rank the steric energies of the possible epimerized forms and correlated those rankings with the relative intensities of MS/MS fragment ions to predict which specific centers had inverted^[1]. The computational approach offered a route to assigning stereo-configuration without the need to synthesize each epimerized reference standard individually, which would be laborious for a cyclic heptapeptide with multiple chiral centers.

The researchers validated their RP-HPLC method over a working concentration range of 25 to 150 micrograms per milliliter, achieving linearity with an r-squared of 0.9993 and satisfactory precision and accuracy. In silico toxicity prediction using ProTox-3.0 placed most of the characterized degradants in toxicity class 5, the second-lowest acute-toxicity band, but the authors note that computational toxicity prediction is a screening tool, not a definitive hazard assessment.

How this connects to Vyleesi's clinical profile

The approved Vyleesi product already carries an FDA-reviewed stability dataset as part of the NDA 210557 dossier. What the Yuvaraaj and Sharma work adds is a more granular public map of bremelanotide's degradation chemistry using modern high-resolution instrumentation, which can inform both generic-development programmes and the academic literature on melanocortin receptor pharmacology. For the approved indication, HSDD in premenopausal women, the RECONNECT phase 3 programme (BMT-301 and BMT-302, Kingsberg and colleagues 2019, approximately 1,247 participants) showed statistically significant improvements in sexual desire and distress over 24 weeks^[2]. A 52-week open-label safety extension found no new safety signals^[3]. Those efficacy and safety results are not altered by the degradant characterization work; the stability chemistry is upstream of the clinical question.

What we do not yet know

The paper does not include in vitro or in vivo biological testing of the eight characterized degradants. Whether any of them retains partial melanocortin receptor agonist activity, or whether any presents a novel safety risk at concentrations plausible in an improperly stored product, is not answered by mass-spectrometric characterization alone. The ProTox-3.0 in silico predictions are hypothesis-generating, not definitive. The authors also did not study the specific storage conditions of grey-market research vials, which are often lyophilized powders that users reconstitute and store without pharmaceutical-grade temperature controls.

Where this sits on the site

The regulatory picture for bremelanotide has not changed: Vyleesi remains prescription-only in the United States and has no marketing authorisation in the EU, EEA, or UK. Grey-market access sits outside any quality framework, and degradant characterization studies like this are part of why that matters practically. For the full regulatory and clinical picture, see the PT-141 peptide page and the PT-141 regulation overview. Any decision about whether to consider bremelanotide for the approved indication belongs with a clinician who knows your medical history.